ESMO

Browse all ESMO
ESMO 2025 Updates in Prostate Cancer: Advances in Radioligand, Genomic, and AR-Targeted Therapies

ESMO

ESMO 2025 Updates in Prostate Cancer: Advances in Radioligand, Genomic, and AR-Targeted Therapies

Michael Serzan, MD

Metastatic Breast Cancer Updates: SERDs, mTOR Inhibitors, and VIKTORIA-1

ESMO

Metastatic Breast Cancer Updates: SERDs, mTOR Inhibitors, and VIKTORIA-1

Erika Hamilton, MD, FASCO, Sarah Premji, MD

5 Key GI Cancer Updates From ESMO 2025

ESMO

5 Key GI Cancer Updates From ESMO 2025

Rachna Shroff, MD, MS, FASCO, Rohit Gosain, MD, Rahul Gosain, MD, MBA

8 Practice-Changing Breast Cancer Presentations From ESMO 2025

ESMO

8 Practice-Changing Breast Cancer Presentations From ESMO 2025

Virginia Kaklamani, MD, DSc, Rahul Gosain, MD, MBA, Rohit Gosain, MD

WCLC

Browse all WCLC
Key NSCLC Trials From WCLC 2025 

WCLC

Key NSCLC Trials From WCLC 2025 

Balazs Halmos, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

ASCO

Browse all ASCO
Preferred Sequencing of Treatment for Neuroendocrine Tumors

ASCO

Preferred Sequencing of Treatment for Neuroendocrine Tumors

Deepak Vadehra, DO, Tanios Bekaii-Saab, MD

Updates in Breast Cancer From ASCO 2025

ASCO

Updates in Breast Cancer From ASCO 2025

Zunairah Shah, MD

Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

ASCO

Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

Kriti Ahuja, MD

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

ASCO

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MD, Narjust Florez, MD, FASCO